Navigation Links
Lixte Biotechnology Receives US Patent for Its Proprietary Histone Deacetylase Inhibitor
Date:4/4/2012

EAST SETAUKET, N.Y., April 4, 2012 /PRNewswire/ -- Lixte Biotechnology Holdings, Inc. announced receiving an official notice of allowance from the United States Patent and Trademark Office for its lead histone deacetylase inhibitor (HDACi), LB-201 and other structural homologs.

Dr. John Kovach, founder and president of Lixte, said, "Although there are HDACi approved for certain types of skin lymphomas and many other HDACi in various stages of development, our compounds have characteristics which may be advantageous for clinical use.  The Lixte compounds also have broad anti-cancer activity but in addition have 1) potential for the treatment of neurodegenerative diseases, for which Lixte recently announced a USPTO patent approval, 2) activity (LB-205) against the lysosomal storage disease, Gaucher Disease, as recently reported in the Proceedings of the National Academy of Science, USA (Dec. 27 2011; 108:21200-5) and 3) curative anti-fungal activity applied topically (LB-201) against the most common skin fungal infections of humans and domestic animals in guinea pig models. As Lixte is predominantly focused on cancer treatment, it is seeking to license the non-neoplastic activities of its proprietary HDACi."

Dr. Kovach continued, "Lixte's primary goal at present is bringing its lead anti-cancer compound, LB-100, into Phase I trial.  We believe this inhibitor of serine/threonine phosphatase has the potential to be first-in-class and to have wide applicability for the treatment of diverse cancers.  LB-100 has completed pre-clinical toxicology and formulation with an anticipated IND submission for FDA approval of a Phase I trial this spring."

About Lixte Biotechnology Holdings, Inc.

Lixte is a cancer drug discovery company, combining selection of novel targets from the medicinal chemistry and molecular biology literature with innovative synthetic chemistry to develop new potentially more effective anti-cancer drugs. It has lead compounds in two classes of drugs, protein phosphatases and novel HDACi for which US patent were recently issued, with world-wide patent applications pending.

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto in the SEC Report on Form 10-QSB for the quarter ending September 30, 2011.

For additional information, please see:  www.Lixte.com


'/>"/>
SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
2. Lixte Biotechnology Holdings Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models
3. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
4. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
5. Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004
6. Global Biotechnology Industry
7. JumpStart Invests $250,000 in Milo Biotechnology
8. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
9. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
10. Animal Biotechnology - Technologies, Markets and Companies
11. Puma Biotechnology Announces Completion of Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
Breaking Biology News(10 mins):